Research programme: cancer therapeutics and diagnostics - BeyondSpring/Fred Hutchinson Cancer Research Center

Drug Profile

Research programme: cancer therapeutics and diagnostics - BeyondSpring/Fred Hutchinson Cancer Research Center

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Jan 2016 Early research in Cancer in USA (unspecified route)
  • 06 Jan 2016 BeyondSpring Pharmaceuticals and Fred Hutchinson Cancer Research Center enter into research collaboration for the development of cancer therapeutics and diagnostics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top